Viagra vs Vardenafil (Levitra/Staxyn): What to Do When One Fails

How Sildenafil and Vardenafil Work: Same Target, Different Profiles

Both drugs block phosphodiesterase type 5 (PDE5), the enzyme that degrades cyclic GMP in corpus cavernosum smooth muscle. By slowing cGMP breakdown, they allow nitric-oxide-driven vasodilation to persist long enough for an erection sufficient for intercourse. The mechanism is identical. The pharmacology is not.

Potency and Receptor Selectivity

Vardenafil has a higher binding affinity for PDE5 than sildenafil, requiring roughly one-tenth the molar concentration to achieve the same inhibitory effect [1]. That translates to therapeutic doses of 5 to 20 mg for vardenafil versus 25 to 100 mg for sildenafil.

Sildenafil also inhibits PDE6, the enzyme that governs phototransduction in retinal rods and cones. This cross-reactivity explains the blue-tint visual disturbance (cyanopsia) reported by 3 to 11% of men taking the 100 mg dose in key trials [2]. Vardenafil has slightly lower PDE6 affinity, making ocular side effects less common, though not absent.

Onset and Duration

Both drugs become pharmacologically active within 30 to 60 minutes of ingestion under typical conditions. In the Porst et al. Head-to-head crossover study (N=52), vardenafil 10 mg produced successful intercourse attempts in a higher proportion of patients than sildenafil 50 mg at the 25-minute mark [3]. Duration of effect extends approximately 4 to 5 hours for both compounds, though individual variation is significant.

The Food Interaction Difference

A high-fat meal reduces sildenafil peak plasma concentration (Cmax) by roughly 29% and delays time to peak (Tmax) by approximately 60 minutes [2]. Vardenafil film-coated tablets (Levitra) show a similar pattern with high-fat meals. The orally disintegrating tablet formulation (Staxyn 10 mg) bypasses first-pass metabolism through buccal absorption to a partial degree, making it less sensitive to food timing, though it is not bioequivalent to Levitra and should not be substituted on a 1:1 basis.

Trial Evidence: What the Data Actually Show

Understanding the trial record is the only way to set realistic expectations before switching agents.

Sildenafil: The Goldstein 1998 NEJM Trial

The landmark sildenafil registration trial by Goldstein et al. Enrolled 532 men with erectile dysfunction of varied etiology. At 100 mg, 69% of all sexual attempts were successful, compared with 22% on placebo [1]. The International Index of Erectile Function (IIEF) erectile-function domain score improved by a mean of 7.0 points over baseline. Men with diabetes and those with radical prostatectomy showed lower but still statistically significant response rates.

Vardenafil: Porst 2003 Crossover Data

Porst et al. Conducted a double-blind, crossover comparison in men who had previously taken sildenafil. Vardenafil 20 mg produced IIEF erectile-function domain scores that were non-inferior to sildenafil 100 mg, and a subset of prior sildenafil partial-responders showed improved scores on vardenafil [3]. The study was limited by its small sample (N=52) and short treatment periods, but it remains one of the only prospective head-to-head crossover datasets available.

What "Failure" Actually Means in Practice

"Failure" is frequently misclassified. The FDA prescribing information for sildenafil specifies that the drug should be taken on at least four separate occasions under optimal conditions (sufficient arousal, no recent high-fat meal, correct timing) before concluding it is ineffective [2]. Published audits suggest that up to 50% of men who report sildenafil failure had never taken the 100 mg dose, had taken it after a large meal, or had not waited the recommended interval [4]. The same applies to vardenafil.

Why Men Switch: The Common Failure Scenarios

Men seek a switch for two broad reasons: the drug does not work well enough, or the side-effect profile is unacceptable. Each scenario has a different clinical pathway.

Insufficient Efficacy

If sildenafil 50 mg fails, the first step is dose escalation to 100 mg, the maximum approved dose. Only after documented failure at 100 mg (under optimal conditions, on at least four attempts) does cross-drug switching become the next logical intervention. A 2016 systematic review found that 40 to 60% of men who fail one PDE5 inhibitor respond adequately to a second agent from the same class, often simply because of pharmacokinetic differences that better match an individual's metabolism [4].

Vardenafil's higher potency per milligram may benefit men whose cytochrome P450 3A4 activity metabolizes sildenafil unusually fast, leading to subtherapeutic plasma levels. CYP3A4 inhibitors such as ketoconazole or erythromycin raise plasma levels of both drugs and require dose reduction; CYP3A4 inducers such as rifampin can lower levels enough to cause apparent treatment failure without any true pharmacodynamic non-response.

Intolerable Side Effects

Sildenafil's more prominent PDE6 cross-reactivity makes it the more likely offender for visual side effects. Men who experience persistent cyanopsia or photosensitivity at 100 mg may tolerate vardenafil 20 mg with fewer or no visual complaints.

Headache, flushing, and nasal congestion arise from vasodilation and occur with both drugs at comparable rates. Dyspepsia is somewhat more common with sildenafil due to PDE5 inhibition in esophageal smooth muscle. Men bothered by reflux symptoms may find vardenafil slightly better tolerated on that specific parameter.

A Structured Switching Protocol

The following framework reflects current evidence-based practice and the HealthRX medical team's clinical approach to PDE5 inhibitor switching. It is reviewed by board-certified urologists and endocrinologists.

Step 1: Confirm True Failure at Maximum Dose

Document at least four failed attempts with sildenafil 100 mg (or vardenafil 20 mg, if that was the starting drug) under these conditions:

• Taken on an empty stomach or after a low-fat meal
• 45 to 60 minutes before anticipated sexual activity
• With adequate sexual stimulation (PDE5 inhibitors are not aphrodisiacs)
• Without concurrent alcohol above one standard drink

Failure confirmed under these conditions is genuine pharmacological non-response or non-response related to underlying pathophysiology, not administration error.

Step 2: Rule Out Treatable Underlying Causes

Before switching, assess the following:

Testosterone. Hypogonadism blunts PDE5 inhibitor response. A total testosterone below 300 ng/dL on two morning fasting samples warrants treatment before or alongside PDE5 inhibitor therapy [5]. The Endocrine Society's 2018 Clinical Practice Guideline recommends testosterone therapy in symptomatic men with consistently low testosterone levels [5].

Cardiovascular disease. Severe endothelial dysfunction reduces the nitric oxide substrate these drugs depend on. Men with poorly controlled hypertension or coronary artery disease may need cardiologic clearance and optimized cardiovascular therapy before expecting full PDE5 response.

Psychogenic overlay. Performance anxiety can suppress the central arousal signal even when drug levels are adequate. Brief CBT interventions improve PDE5 inhibitor response rates in men with mixed organic and psychogenic ED.

Step 3: Switch and Re-Titrate from the Lowest Effective Dose

When crossing from sildenafil to vardenafil, start at vardenafil 10 mg (not 20 mg), because the higher potency means a lower starting dose may already exceed what sildenafil 100 mg provided. If 10 mg is well tolerated but insufficient after four attempts, titrate to 20 mg. Starting at the top dose risks disproportionate hypotension in men who are also on alpha-blockers.

When crossing from vardenafil to sildenafil (less common, usually driven by cost or formulary access), begin at sildenafil 50 mg and optimize conditions rigorously before escalating.

Step 4: Evaluate at Six Weeks

A six-week re-evaluation using the IIEF-5 questionnaire (score range 5 to 25, with scores below 22 indicating some degree of dysfunction) gives a structured, reproducible endpoint. Improvement of 4 or more IIEF-5 points is considered a clinically meaningful change. If the score has not improved by week six at maximum dose under optimal conditions, a urologic referral for further workup, including penile Doppler ultrasound or intracavernosal injection testing, is appropriate.

Drug Interactions and Safety Considerations for Both Agents

Both sildenafil and vardenafil carry an absolute contraindication with any form of nitrate, including sublingual nitroglycerin, isosorbide mononitrate, isosorbide dinitrate, and recreational nitrates (poppers). Co-administration can produce a potentially fatal drop in blood pressure, with case reports documenting systolic drops exceeding 50 mmHg [2].

Alpha-Blocker Interactions

Alpha-blockers (tamsulosin, doxazosin, alfuzosin) used for benign prostatic hyperplasia can produce additive hypotension with PDE5 inhibitors. The FDA prescribing label for vardenafil (Levitra) specifies a minimum 6-hour gap between tamsulosin and vardenafil doses. Sildenafil's label requires similar caution. Starting any PDE5 inhibitor at the lowest dose in men on alpha-blockers is standard practice.

QTc Prolongation: A Vardenafil-Specific Concern

Vardenafil prolongs the QTc interval in a dose-dependent manner. At 10 mg, the mean QTc increase was approximately 8 milliseconds in pharmacokinetic studies [6]. At 80 mg (a supratherapeutic dose used for testing), the mean increase reached 16 milliseconds. Men with congenital long QT syndrome, those on Class IA antiarrhythmics (quinidine, procainamide), or those on Class III antiarrhythmics (sotalol, amiodarone) should not take vardenafil. Sildenafil shows no clinically meaningful QTc effect at therapeutic doses.

Renal and Hepatic Impairment

Neither drug requires dose adjustment for mild-to-moderate renal impairment, but both should be initiated at the lowest dose in men with hepatic impairment (Child-Pugh A or B), because reduced first-pass metabolism increases peak plasma concentrations. Vardenafil is not recommended in Child-Pugh C (severe hepatic impairment).

Special Populations: Where the Drugs Diverge Clinically

Men With Diabetes

Diabetic men have lower baseline nitric oxide bioavailability and more severe endothelial dysfunction. Both drugs show reduced absolute response rates in this population compared to non-diabetic men, but vardenafil 20 mg demonstrated statistically significant IIEF improvement over placebo in a dedicated diabetic cohort study (N=452, P<0.001) [7]. Sildenafil showed comparable results in the Goldstein trial subgroup analysis [1].

Men After Radical Prostatectomy

Nerve-sparing prostatectomy patients have the lowest response rates to any oral PDE5 inhibitor. Both sildenafil and vardenafil show partial response in bilateral nerve-sparing cases but minimal response after non-nerve-sparing surgery. A 2004 trial by Brock et al. Showed vardenafil 10 mg and 20 mg significantly improved IIEF scores versus placebo in post-prostatectomy men, with 71% of men on 20 mg achieving vaginal penetration [8].

Older Men

Age-related declines in CYP3A4 activity increase plasma levels of both drugs. Men over 65 should start at sildenafil 25 mg or vardenafil 5 mg and titrate based on response and tolerability rather than jumping to standard starting doses.

Cost, Availability, and Formulation Considerations

Generic sildenafil has been available in the United States since 2017, making 100 mg tablets widely accessible at $1 to 5 per dose through major pharmacy chains. Generic vardenafil became available after Bayer's patent expiration and is substantially cheaper than branded Levitra, though it remains more expensive than generic sildenafil in most markets.

Staxyn (orally disintegrating vardenafil 10 mg) does not have a generic equivalent and carries a branded price premium. Its convenience for men who have difficulty swallowing tablets may justify the cost difference in select cases, but it should not be used interchangeably with film-coated vardenafil due to different bioavailability profiles.

Sildenafil 20 mg tablets, originally marketed as Revatio for pulmonary arterial hypertension, are sometimes prescribed off-label in three-tablet increments (totaling 60 mg) as a lower-cost alternative to branded Viagra. This is a recognized clinical workaround but requires a physician's explicit guidance on dosing to avoid under-treatment.

When to Move Beyond PDE5 Inhibitors Entirely

If both sildenafil 100 mg and vardenafil 20 mg fail under rigorously optimized conditions, the clinical decision tree branches into three main paths.

Tadalafil (Cialis). Tadalafil's 17.5-hour half-life and different pharmacokinetic profile mean it may produce a response in some PDE5 inhibitor partial-responders, particularly those whose relationship with timed dosing contributes to psychological performance pressure. The 5 mg once-daily regimen produces stable plasma levels that may suit men who do not respond reliably to on-demand dosing.

Intracavernosal injection therapy. Alprostadil injected directly into the corpus cavernosum bypasses the nitric oxide pathway entirely. Response rates exceed 85% across most etiologies of ED, including men who failed all three oral PDE5 inhibitors [9]. The discontinuation rate is high due to injection-site discomfort, but the pharmacological efficacy is the highest available for non-surgical therapy.

Penile prosthesis. For men with complete non-response to all pharmacological options, inflatable penile prostheses offer satisfaction rates of 90 to 95% at three years in published device registries [9]. Referral to a urologist specializing in sexual medicine is the appropriate next step at this juncture.

The American Urological Association's 2018 Erectile Dysfunction Guideline states: "Patients should be informed that PDE5 inhibitors are contraindicated in men taking any form of nitrates and should be counseled about the stepwise approach to managing treatment failure." [10]